Screener
Intellia Therapeutics NTLA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accrued expenses | (5,591) | (13,583) |
| Deferred revenue | (7,290) | (9,224) |
| Operating lease liabilities | (17,836) | (45,690) |
| Net cash used in operating activities | (200,459) | (248,552) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property and equipment | (1,888) | (974) |
| Proceeds from sale of property and equipment | 90 | - |
| Purchases of marketable securities | (267,358) | (138,809) |
Item 1. Financial Statements
FAQ
- What is Intellia Therapeutics's operating cash flow?
- Intellia Therapeutics (NTLA) reported operating cash flow of -$83.11M in Q2 2026.
- How has Intellia Therapeutics's operating cash flow changed year-over-year?
- Intellia Therapeutics's operating cash flow increased by 16.6% year-over-year, from -$99.62M to -$83.11M.
- What is the long-term trend for Intellia Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Intellia Therapeutics's operating cash flow has grown at a 15.1% compound annual growth rate (CAGR), from -$225.03M to -$394.74M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Intellia Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude